Agios Pharmaceuticals Inc banner

Intrinsic Value

The intrinsic value of Agios Pharmaceuticals Inc (8AP) under the Base Case is 38.83 EUR per share. Compared with the current market price of 28.2 EUR, the stock appears Undervalued by 27% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

8AP Intrinsic Value
€38.83
Undervaluation 27%
Intrinsic Value
Price €28.2
Alert me when 8AP is below its intrinsic value
Today €27.18 · 3.6% below the current price

8AP is cheaper than usual. It was this cheap or cheaper on just 5% of days in the past 5 years.

Alternatives to 8AP

Fundamental Analysis

What Agios Pharmaceuticals Does

Biotechnology Health Care

Agios Pharmaceuticals is a biotech company that develops medicines for rare blood disorders. Its main approved drug is Pyrukynd, a pill used to treat certain inherited anemia conditions by helping red blood cells make energy more efficiently. The company also keeps working on other drug candidates in rare hematology, using the same idea of targeting cell metabolism.

Headquarters
United States of America US
Employees
539
IPO date
Jul 24, 2013
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Agios Pharmaceuticals insiders are selling within their usual range

Insider trading · Last trade on Oct 26, 2026

Sold $3.6m 7 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Continue 8AP Research

Decided on Agios Pharmaceuticals? Get an email when 8AP reaches the price you’d buy at. Free with an account.

Other Agios Pharmaceuticals listings

What is the Intrinsic Value of one 8AP stock?

The intrinsic value for Agios Pharmaceuticals Inc (8AP) under the Base Case is 38.83 EUR.

Is 8AP stock undervalued or overvalued?

Compared with the current market price of 28.2 EUR, the stock appears Undervalued by 27% .

How reliable are our estimates? See how past valuations played out
Back to Top